Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cellebrite DI (CLBT) Research & Development (2020 - 2025)

Historic Research & Development for Cellebrite DI (CLBT) over the last 6 years, with Q3 2025 value amounting to $28.1 million.

  • Cellebrite DI's Research & Development rose 847.8% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.6 million, marking a year-over-year increase of 1590.83%. This contributed to the annual value of $98.4 million for FY2024, which is 1662.48% up from last year.
  • As of Q3 2025, Cellebrite DI's Research & Development stood at $28.1 million, which was up 847.8% from $28.6 million recorded in Q2 2025.
  • Cellebrite DI's Research & Development's 5-year high stood at $28.6 million during Q2 2025, with a 5-year trough of $14.9 million in Q1 2021.
  • For the 5-year period, Cellebrite DI's Research & Development averaged around $21.7 million, with its median value being $21.1 million (2023).
  • Per our database at Business Quant, Cellebrite DI's Research & Development skyrocketed by 3170.39% in 2022 and then tumbled by 547.26% in 2023.
  • Cellebrite DI's Research & Development (Quarter) stood at $18.8 million in 2021, then increased by 4.78% to $19.7 million in 2022, then rose by 10.22% to $21.8 million in 2023, then increased by 17.69% to $25.6 million in 2024, then rose by 9.86% to $28.1 million in 2025.
  • Its Research & Development stands at $28.1 million for Q3 2025, versus $28.6 million for Q2 2025 and $27.3 million for Q1 2025.